Most Read Articles
28 Apr 2020
Women who skip breakfast before and during early pregnancy have a higher risk of developing gestational diabetes mellitus (GDM) than those who have the essential meal daily, suggests a study.
Pearl Toh, 23 Sep 2020
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 23 Sep 2020

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.

Faecal microbiota transplantation offers little in terms of weight management

17 Apr 2020
Faecal microbiota transplant may soon take on a non-invasive form – encapsulation.

In obese, metabolically uncompromised individuals, faecal microbiota transplantation (FMT) is safe but does not effectively reduce body mass index (BMI), according to the results of a pilot study.

The study included 22 obese individuals without a diagnosis of diabetes, nonalcoholic steatohepatitis or metabolic syndrome. These participants were randomized to receive FMT by capsules (induction dose of 30 capsules at week 4; maintenance dose of 12 capsules at week 8) or placebo capsules. FMT capsules were obtained from a single donor with BMI of 17.5 kg/m2.

Patients were followed for 26 weeks, with stool and serum samples collected at baseline and at weeks 1, 4, 6, 8 and 12 after administration of the first dose of treatment. Researchers analysed the samples using 16S RNA gene sequencing and liquid chromatography–mass spectrometry.

The incidence of adverse events did not significantly differ between patients who received FMT vs placebo. There was no increase in the area under the curve of GLP1 observed in either group.

Patients in the FMT group showed sustained changes in microbiomes associated with obesity toward those of the donor (p<0.001), as well as a sustained decrease in stool levels of taurocholic acid (p<0.05) compared with baseline. Additionally, bile acid profiles started to resemble those of the donor more closely at the end of the intervention.

There were no significant changes documented in mean BMI at week 12 in FMT and placebo groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
28 Apr 2020
Women who skip breakfast before and during early pregnancy have a higher risk of developing gestational diabetes mellitus (GDM) than those who have the essential meal daily, suggests a study.
Pearl Toh, 23 Sep 2020
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 23 Sep 2020

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.